Lectus Therapeutics Ltd’s management team have extensive expertise in ion channel drug discovery, proteomics, chemistry, biology, finance and legal affairs gained from considerable experience within the biotechnology and pharmaceutical industry. The management team is also supported by a world-class core scientific advisory board. |
Advancing Innovation in Bio-Pharmaceutical Research
Lectus Therapeutics Ltd is a pioneering UK-based bio-pharmaceutical company, committed to transforming healthcare through scientific innovation. Established in the summer of 2003, we specialize in the discovery and development of novel drugs aimed at treating diseases associated with smooth muscle hyperreactivity. Our mission is to advance cutting-edge therapeutic solutions that improve patient outcomes and enhance the quality of life for individuals affected by these conditions.
Our Vision
At Lectus Therapeutics, we envision a future where innovative treatments can provide lasting relief for patients suffering from smooth muscle-related diseases. We are dedicated to pushing the boundaries of scientific research, leveraging breakthrough technologies, and accelerating drug discovery to address unmet medical needs.
Our Research & Development Approach
Our approach to drug discovery is rooted in a deep understanding of ion channels and their role in smooth muscle function. By integrating advanced molecular biology, pharmacology, and state-of-the-art drug screening techniques, we are developing novel compounds that have the potential to revolutionize treatment options.
At Lectus Therapeutics, we focus on:
Identifying novel targets that regulate smooth muscle activity
Developing proprietary molecules with high specificity and efficacy
